Background Pre-clinical and clinical evidence suggests that simultaneous blockade of
VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances antigen-specific T-cell migration, …

The anti programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab have
been recently licensed by the Food and Drug Administration for the treatment of advanced …

Lessons Learned Ramucirumab plus pembrolizumab revealed no unexpected safety findings
in patients with advanced or metastatic biliary tract cancer, which is consistent with reports …

The use of agents able to modulate the immune system to induce or potentiate its anti-tumour
activity is not a new strategy in oncology. However, the development of new agents such …

Background Reliable predictive imaging markers of response to immune checkpoint
inhibitors are needed. Purpose To develop and validate a pretreatment CT-based radiomics …

Importance Clinical trial evidence used to support drug approval is typically the only information
on benefits and harms that patients and clinicians can use for decision-making when …

Purpose: Most hyperprogression disease (HPD) definitions are based on tumor growth rate (TGR).
However, there is still no consensus on how to evaluate this phenomenon. Patients …

Background Solitary Fibrous Tumour (SFT) is a rare soft tissue neoplasm, described in several
locations in the body. It is classified as intermediate malignant potential with low risk of …

Background Immunotherapies like the cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab
show durable clinical benefit in patients with advanced melanoma. Reliable prognostic …

Background OX40 is a costimulatory receptor upregulated on antigen-activated T cells and
constitutively expressed on regulatory T cells (Tregs). INCAGN01949, a fully human …